Correlation Engine 2.0
Clear Search sequence regions

  • asthenia (3)
  • brain (1)
  • cognitive functions (2)
  • functions (1)
  • humans (1)
  • impaired (1)
  • ischemia (5)
  • mexidol (5)
  • patients (6)
  • picolines (2)
  • sars cov (1)
  • scale (3)
  • sleep (2)
  • Sizes of these terms reflect their relevance to your search.

    To study the possibility of improving the efficacy of treatment with mexidol in COVID-19 patients with chronic cerebral ischemia (CCI). Three hundred and four patients with CCI and COVID-19 were observed, group 1 (n=152) consisted of patients receiving basic therapy and mexidol, group 2 (n=152) received only basic therapy. Mexidol was administered intravenously for 14 days, 500 mg (10 ml) per 400 ml of saline solution, then Mexidol FORTE 250 was administered in a dose of 250 mg 3 times a day for 2 months. The state of cognitive functions (MoCA scale), sleep (Spiegel questionnaire), asthenia (MFI-20 scale), and quality of life (SIP questionnaire) were evaluated. Examinations were performed before treatment, 30 and 75 days after start of treatment. In group 1, there was a more complete and earlier recovery of the state of cognitive functions (an increase in indicators on the MoCA scale, p<0.01), a regression of asthenia (p<0.05), and normalization of sleep (p<0.01). By the end of the study, there were significantly more patients in group 1 with complete or significant recovery of all quality of life indicators. Long-term sequential therapy with mexidol provides a more complete recovery of impaired functions in patients with CCI and COVID-19.


    V V Kovalchuk, I I Ershova, N V Molodovskaya. Possibilities of improving the effectiveness of therapy in patients with chronic cerebral ischemia against the background of COVID-19]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2021;121(3. Vyp. 2):60-66

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 33908234

    View Full Text